Cynthia Mubanga

With 14 years of diverse experience in clinical and research laboratory environments, bringing a robust skill set honed through collaboration with government health ministries and non-profit organizations. Proficient across various laboratory assays encompassing microbiology, immunology, and molecular biology, with expertise leaning towards immunological responses to vaccines. Currently in the final year of PhD in Medical Microbiology and Immunology studies with a research focus on systemic memory responses to a candidate vaccine against Enterotoxigenic E.coli in Zambian children aged 6-23 months.

In addition to research pursuits, contributed to microbiology initiatives and provided mentorship in both microbiology and antimicrobial resistance (AMR) monitoring within clinical settings. Recognized for organizational skills and reliability, excelling in managing multiple priorities while maintaining a positive outlook. Committed to team success, I eagerly embrace additional responsibilities to advance collective objectives.

• African Society for Laboratory Medicine (ASLM)
• Biomedical Society of Zambia (BMSZ)
• American Society for Microbiology (ASM)
• Bactivac Network
• Immunology Society of Zambia (ISZ)

• Seroepidemiology of hepatitis E virus infection in an urban population in Zambia: strong association with HIV and environmental enteropathy, Journal of Infectious Diseases, 2013, Jacobs C, Chiluba C, Phiri C, Lisulo M.M, Chamba M, et al, 209, 5, 652-657
• Impact Of Rotavirus Vaccination On Diarrheal Hospitalisations In Children Aged Under Five In Lusaka, Zambia, Journal of clinical infectious Diseases, 2016, Mpabalawani E.M, Simwaka C.J, Mwenda J.M, Mubanga C.P, Monze M, et al, 62, suppl2, S183
• Seroprevalence of arthropod-borne viral infections among Lukanga swamp residents in Zambia, PLOS ONE, 2020, Chisenga CC, Bosomprah S, Musukuma K, Mubanga C, Chilyabanyama ON, et al., 15, 7
• In-vitro inhibitory effect of maternal breastmilk components on rotavirus vaccine replication and association with infant seroconversion to live oral rotavirus vaccine, PLOS ONE, 2020, Kazimbaya KM, Chisenga CC, Simuyandi M, Phiri CM, Laban NM, et al., 15, 11
• Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia, PLOS ONE, 2021, Charlie Chaluma Luchen, John Mwaba, Harriet Ng’ombe, Peter Ibukun Oluwa Alabi, Michelo Simuyandi, Obvious N. Chilyabanyama, Luiza Miyanda Hatyoka, Cynthia Mubanga et al., 16, 12
• Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol) in adults residing in Lukanga Swamps of Zambia, PLOS ONE, 2022, Harriet Ngombe, Michelo Simuyandi, John Mwaba, Charlie Chaluma Luchen, Peter Alabi, Obvious Nchimunya Chilyabanyama, Cynthia Mubanga et al., 17, 1
• Use of an ETEC ProteomeMicroarray to Evaluate Cross-Reactivity of ETVAX Vaccine-Induced IgG Antibodies in Zambian Children, Vaccines, 2023, Cynthia Mubanga, Michelo Simuyandi, Kapambwe Mwape, Kennedy Chibesa, Caroline Chisenga, Obvious Nchimunya Chilyabanyama, Arlo Randall, Xiaowu Liang, Richard H. Glashoff and Roma Chilengi, 2023, 11, 939
• Evaluation of ROTARIX Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial, Vaccines, 2023, Laban NM, Bosomprah S, Simuyandi M, Chibuye M, Chauwa A, Chirwa-Chobe M, Sukwa N, Chipeta C, Velu R, Njekwa K, Mubanga C, Mwape I, Goodier MR, Chilengi R., 11, 2, 346
• Maternal and Infant Histo-Blood Group Antigen (HBGA) Profiles and Their Influence on Oral Rotavirus Vaccine (RotarixTM) Immunogenicity among Infants in Zambia, Vaccines, 2023, Chauwa A, Bosomprah S, Laban NM, Phiri B, Chibuye M, Chilyabanyama ON, Munsaka S, Simuyandi M, Mwape I, Mubanga C, Chobe MC, Chisenga C, Chilengi R., 11, 8, 1303
• Prevalence of Diarrhoeagenic Escherichia coli among Children Aged between 0–36 Months in Peri-Urban Areas of Lusaka, Microorganisms, 2023, Mwape K.; Bosomprah S.; Chibesa K.; Silwamba S.; Luchen, C.C.; Sukwa, N.; Mubanga, C.; Phiri, B.; Chibuye, M.; Liswaniso, F.; et al., 11, 11, 2790
• Application of a Novel Proteomic Microarray Reveals High Exposure to Diarrhoeagenic Escherichia coli among Children in Zambia Participating in a Phase I Clinical Trial, Microorganisms, 2024, Mwape K, Mubanga C, Chilyabanyama ON, Chibesa K, Chisenga CC, Silwamba S, Randall A, Liang X, Barnard TG, Simuyandi M, et al., 12, 3, 420
• Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial, Vaccine, 2023, Nsofwa Sukwa, Cynthia Mubanga, Luiza M. Hatyoka, Obvious N. Chilyabanyama, Mwelwa Chibuye, Samson Mundia, Masiliso Munyinda, Ethel Kamuti, Muyunda Siyambango, Sharif Badiozzaman, Samuel Bosomprah, Nils Carlin, Joanna Kaim, Björn Sjöstrand, Michelo Simuyandi, Roma Chilengi, Ann-Mari Svennerholm, 41, 46, 6884-6894
• The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations, Vaccine, 2023, Banerjee S, Barry EM, Baqar S, Louis Bourgeois A, Campo JJ, Choy RKM, Chakraborty S, Clifford A, Deal C, Estrada M, Fleckenstein J, Hasso-Agopsowicz M, Hausdorff W, Khalil I, Maier N, Mubanga C, Platts-Mills JA, Porter C, Qadri F, Simuyandi M, Walker R, White JA, Epub ahead of print

• Prof. Roma Chilengi, Director General, Zambia National Public Health Institute, Lusaka, Zambia, chilengir@yahoo.com, +26073724935
• Dr. Mwaka Monze, Unit Head, Virology Laboratory, University Teaching Hospital, Lusaka, Zambia, mwakamonze@hotmail.com, +260977793654
• Dr. Nicksy Gumede, WHO Afro Regional Virologist, Brazaville, Congo, gumedemoeletsih@who.int, +27834922794

• October 2023, 4th Annual Bactivac meeting, Poster Presenter, Cross-reactivity of the ETVAX vaccine-induced IgG antibodies to non-vaccine ETEC antigens and Diarrhoeagenic Escherichia coli specific antigens: A microarray analysis
• October 2022, Zambia National Health Research Conference, Lusaka, Zambia, Oral Presenter, Use of an ETEC proteome microarray to evaluate cross-reactivity of ETVAX vaccine induced IgG antibodies in Zambian children
• November 2022, Vaccines against Shigella and ETEC (VASE) Conference, Washington DC, USA, Oral Presenter, Cross-reactivity of the ETVAX vaccine-induced IgG antibodies to non-vaccine ETEC antigens and Diarrhoeagenic Escherichia coli specific antigens: A microarray analysis
• Good Clinical Practice (GCP), RCR, January 2022
• African Advanced Vaccinology course, September 2021, Wits University
• GCP, RCR, November 2018
• Quality Management systems (QMS), September 2016, MOH
• Infectious substance shippers training, May 2016, WHO
• African Regional Biosafety workshop, October 2015, CDC
• Surveillance of vaccine-preventable diseases, August 2015, WHO
• Integrated Polio Lab database, May 2015, WHO
• Estimating HIV-1 incidence using the LAg-Avidity EIA, September 2014, CDC
• Polio/ enterovirus isolation and intratypic differentiation by rRT-PCR, June 2014, WHO
• Influenza virus isolation, November 2013, WHO
• Early infant diagnosis for HIV and HIV viral load testing using Cobas Ampliprep/Taqman 48, May 2013, Roche Diagnostics
• Supply chain management system, 2011, MOH